 LogicBio Therapeutics Inc NASDAQ: LOGC shares are trading higher by 63.48 at 0.81 after the company announced the FDA lifted the clinical hold on its LB-001 Investigational New Drug Application, allowing patient enrollment to resume in the Phase 12 SUNRISE trial for pediatric patients with. 